

# The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection

Trevor A. Stump, PharmD, BCPP<sup>1</sup>; Leigh Anne Nelson, PharmD, BCPP<sup>2</sup>; Yifei Liu, BS Pharm, PhD<sup>3</sup>; Carrie R. Kriz, MS<sup>4</sup>; Courtney A. Iuppa, PharmD, BCPP<sup>5</sup>; Lauren A. Diefenderfer, PharmD, BCPP<sup>6</sup>; Shelby E. Lang, PharmD, BCPP<sup>7</sup>; Ellie S. R. Elliot, PharmD, BCPP<sup>8</sup>; Roger W. Sommi, PharmD, BCPP, FCCP<sup>9</sup>

**How to cite:** Stump TA, Nelson LA, Liu Y, Kriz CR, Iuppa CA, Diefenderfer LA, et al. The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection. *Ment Health Clin* [Internet]. 2021;11(1):12-8. DOI: 10.9740/mhc.2021.01.012.

## Abstract

**Introduction:** Dosing recommendations for paliperidone long-acting injectable antipsychotic (LAIA) do not include oral antipsychotic (OAP) overlap; however, OAPs are often given concurrently despite limited evidence describing both the risks and benefits of this practice.

**Methods:** A retrospective chart review was conducted in patients initiated on paliperidone palmitate (PP) during a psychiatric hospitalization to compare patients who received OAP overlap versus those who did not. The primary outcome is the proportion of patients who receive prescription claims for benzotropine, a medication commonly prescribed for extrapyramidal symptoms, at the time of LAIA discontinuation and 6 months postdischarge. Secondary outcomes include prescription claims for beta blockers and diphenhydramine, number of psychiatric emergency visits and hospitalizations, length of stay of the index hospitalization, frequency of LAIA discontinuation and the time to LAIA discontinuation.

**Results:** There is a significant difference in the proportion of benzotropine prescription claims in the OAP overlap group versus the no-overlap group at the time of LAIA discontinuation (30% vs 0%,  $P=.046$ ) but not at 6 months postdischarge. There are also significant differences in the number of psychiatric emergency visits (0.7 vs 0.1,  $P=.02$ ) and psychiatric hospitalizations (0.6 vs 0.1,  $P=.029$ ) at the time of LAIA discontinuation. No other differences are observed in defined secondary outcomes.

**Discussion:** Patients who receive OAP overlap while receiving PP receive more benzotropine and have more psychiatric emergency visits and hospitalizations than those treated without OAP. Larger studies with better control for confounding variables are needed to confirm these results.

**Keywords:** paliperidone palmitate, long-acting injectable antipsychotic, oral antipsychotic overlap, benzotropine, adverse events, decompensation

<sup>1</sup> Behavioral Health Clinical Pharmacist, Cleveland Clinic Marymount Hospital, Cleveland, Ohio, ORCID: <https://orcid.org/0000-0003-2207-6607>; <sup>2</sup> (Corresponding author) Professor of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, [nelsonla@umkc.edu](mailto:nelsonla@umkc.edu), ORCID: <https://orcid.org/0000-0003-1481-8682>; <sup>3</sup> Associate Professor of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0003-3597-8706>; <sup>4</sup> Clinical Research Coordinator, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0002-2515-3156>; <sup>5</sup> Clinical Manager, Center for Behavioral Medicine, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0003-1038-0791>; <sup>6</sup> Clinical Pharmacist, Center for Behavioral Medicine, Kansas City, Missouri,

ORCID: <https://orcid.org/0000-0002-1641-8327>; <sup>7</sup> Clinical Pharmacist, Center for Behavioral Medicine, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0003-4511-1735>; <sup>8</sup> Director of Pharmacy, Center for Behavioral Medicine, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0002-2458-6486>; <sup>9</sup> Associate Dean, Vice Chair and Professor of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, ORCID: <https://orcid.org/0000-0001-8110-8467>

**Disclosures:** L.A.N. reports that she is on the speaker's bureau of Alkermes and has received research grant support from Alkermes; Janssen Scientific Affairs, LLC; Otsuka Pharmaceutical Development & Commercialization, Inc; Neurocrine Pharmaceuticals; Boehringer Ingelheim; and Teva Pharmaceu-

tical Industries, Ltd. Y.L. has received research grant support from Alkermes. R.W.S. is on the speaker's bureau of Alkermes; Janssen Scientific Affairs, LLC; and Sunovion and has received research grant support from Alkermes; Janssen Scientific Affairs, LLC; Otsuka Pharmaceutical Development & Commercialization, Inc; Neurocrine Pharmaceuticals; Boehringer Ingelheim; and Teva Pharmaceutical Industries, Ltd. T.A.S., C.R.K., C.A.I, L.A.D., S.E.L., and E.S.R.E. have nothing to disclose.

## Introduction

Long-acting injectable antipsychotics (LAIA) were developed with the goal of improving adherence and preventing relapse in patients with psychotic disorders.<sup>1-3</sup> LAIAs have been shown to prevent psychiatric hospitalizations in patients previously treated with oral antipsychotics (OAPs), promote medication adherence, and prevent relapse in patients with early phase or first-episode psychosis.<sup>1,4-8</sup> LAIAs are designed to slowly release medication, providing extended antipsychotic coverage. As a result of this slow release and delayed onset, product labeling for different LAIAs recommend strategies such as OAP overlap or specific initiation doses to achieve therapeutic concentrations. Despite these recommendations, OAPs are commonly continued concomitantly with LAIAs contrary to recommendations in the product labeling with studies reporting concurrent prescribing frequencies of 21%-76%.<sup>9-24</sup>

Paliperidone palmitate (PP) is a second-generation antipsychotic available in 2 LAIA formulations.<sup>15,16</sup> The product labeling for the monthly PP recommends a 2-dose regimen when initiating PP.<sup>15</sup> In model-based pharmacokinetic simulations, this initiation regimen reaches therapeutic plasma concentrations within the first week for 84% of patients and maintains these concentrations on days 8 and 36 for 90% of patients.<sup>17-19</sup> The product labeling recommends caution when administering PP with oral paliperidone or risperidone, which is metabolized to paliperidone, due to the limited safety data available for this combination.<sup>15,16</sup>

Although most studies focused on LAIA and OAP prescribing patterns, only 3 studies<sup>11,20,21</sup> reported any tolerability or efficacy outcomes as a result of using LAIA and OAP concomitantly. One study<sup>11</sup> describing the prevalence of concomitant LAIA and OAP prescribing in a veteran population incidentally found no difference in prescriptions for the treatment of EPS in patients receiving both LAIAs and OAPs versus those receiving LAIAs alone. A second study<sup>20</sup> assessing differences between patients treated with long-acting olanzapine with or without oral olanzapine supplementation found that participants who received oral supplementation were more likely to drop out of the study for any cause. Finally a retrospective chart review<sup>21</sup> assessed the effects of OAP overlap with risperidone on patients initiated on PP. The

study calculated a reduction in hospitalization days based on total hospitalization days in the 6 months before and after PP initiation. Patients who received at least 7 days of oral risperidone following PP initiation had a significantly larger decrease in hospitalization days.<sup>21</sup>

Contrary to recommendations in the product labeling, oral paliperidone and risperidone are commonly continued concurrently with PP, and little is known about the consequences or benefits of this concurrent use. Because the initiation regimen of PP is designed to achieve therapeutic plasma concentrations independent of OAP overlap,<sup>15,17-19</sup> little is known about the impact of this practice on the efficacy of PP, and patients may be at risk for adverse effects with concurrent oral use. The objective of this study is to assess the effects of concurrent OAP overlap with paliperidone or risperidone and PP.

## Methods

This study was a single-site retrospective chart review of PP use and concurrent OAP overlap at an acute care psychiatric facility. IRB and facility approval was obtained prior to data collection. Patients were included if they were 18 years or older, had active Medicaid coverage at discharge, and received the 2-dose initiation regimen of PP while admitted to the facility between January 1, 2017, and June 30, 2018. Patients were excluded if they were discharged to correctional, residential treatment, or skilled nursing facilities. Patients discharged to such facilities may not have reliable prescription claims data. Additionally, the monitoring of medication adherence would likely be a confounding variable for some of our secondary outcomes, such as the proportion of patients who discontinued their LAIA and the number of days to LAIA discontinuation.

Baseline demographics and data from the index hospitalization were collected using Cerner electronic health record. Subsequent LAIA administration, psychiatric emergency visits, and psychiatric hospitalizations for the 6 months following discharge were collected through Missouri HealthNet's CyberAccess electronic health record, which provided access to prescription, procedural, and other Medicaid claims data. Following screening for inclusion, patients were divided into 2 groups based on concurrent OAP use. Patients who received at least 1 dose of oral paliperidone or risperidone after their first PP LAI injection were assigned to the oral overlap group.

The primary outcome of this study was the proportion of patients with prescription claims for benzotropine, a medication commonly prescribed to treat EPS. This outcome was chosen as a surrogate marker for adverse effects. Secondary outcomes included the proportion of patients who received prescription claims for beta

**TABLE 1: Baseline demographics and concurrent medication use**

	All Patients (n = 33)	Overlap (n = 13)	No Overlap (n = 20)	P Value
Age, y, mean ± SD	35.3 ± 11.8	40 ± 12.9	32.2 ± 10.1	.061
Male, n (%)	17 (51.5)	7 (53.8)	10 (50.0)	.829
Race, n (%)				
White	17 (51.5)	8 (61.5)	9 (45.0)	.353
African American	14 (42.4)	4 (30.8)	10 (50.0)	.275
Other	2 (6.1)	1 (7.7)	1 (5.0)	1.000
Primary diagnosis, n (%)				
Schizophrenia	15 (45.5)	6 (46.2)	9 (45.0)	.948
Schizoaffective	5 (15.2)	2 (15.4)	3 (15.0)	1.000
Bipolar disorder	4 (12.1)	1 (7.7)	3 (15.0)	1.000
Psychosis NOS	7 (21.2)	4 (30.8)	3 (15.0)	.393
Other	2 (6.1)	0 (0)	2 (10.0)	.508
BMI, kg/m <sup>2</sup> , mean ± SD	27.9 ± 8.4	28 ± 10	27.8 ± 7.5	.928
History of PP, n (%)	14 (42.4)	7 (53.8)	7 (35.0)	.284
PP maintenance dose, mg, n (%)				
234	3 (9.1)	1 (7.7)	2 (10.0)	1.000
156	27 (81.8)	12 (92.3)	15 (75.0)	.364
117	3 (9.1)	0 (0)	3 (15.0)	.261
Medication use during admission, n (%)				
Antipsychotic <sup>a,b</sup>	27 (81.8)	10 (76.9)	17 (85.0)	.659
Antidepressant	8 (24.2)	3 (23.1)	5 (25.0)	1.000
Mood stabilizer	2 (6.1)	2 (15.4)	0 (0)	.148
Medication at PP discontinuation, n (%)				
Antipsychotic <sup>a,b</sup>	8 (30.1) <sup>c</sup>	5 (50) <sup>d</sup>	3 (18.8) <sup>e</sup>	.189
Antidepressant	3 (11.5) <sup>c</sup>	2 (20) <sup>d</sup>	1 (6.3) <sup>e</sup>	.538
Mood stabilizer	5 (19.2) <sup>c</sup>	4 (40) <sup>d</sup>	1 (6.3) <sup>e</sup>	.055

NOS = not otherwise specified; PP = paliperidone palmitate.

<sup>a</sup>Includes as-needed medications.

<sup>b</sup>Antipsychotics excluding oral paliperidone or risperidone.

<sup>c</sup>Only includes patients who discontinued long-acting injectable antipsychotic (n = 26).

<sup>d</sup>Only includes patients who discontinued long-acting injectable antipsychotic (n = 10).

<sup>e</sup>Only includes patients who discontinued long-acting injectable antipsychotic (n = 16).

blockers or diphenhydramine, the number of psychiatric emergency visits, the number of psychiatric hospitalizations, the average length of stay of the index hospitalization, the proportion of patients who discontinued their LAIA, and the number of days to LAIA discontinuation. All outcomes for the study were assessed at 2 time points: at the time of LAIA discontinuation and at 6 months after discharge. LAIA discontinuation was defined as 45 days after the last documented administration of PP to account for late doses.

Pearson correlations were utilized to identify variables that correlated with OAP overlap use. These results were then confirmed with chi-square or Fisher exact tests for categorical variables, and *t*-tests for continuous variables.

## Results

An initial 142 patients were screened for study eligibility. Of these patients, 33 met inclusion criteria, and 13 received oral overlap. Most patients were excluded for lack of Medicaid coverage for the entire 6-month follow-up period. Demographic information is included in Table 1. Overall, the sample was balanced by gender (51.5% male) and race (51.5% White, 42.4% African American). Most patients had a primary diagnosis of schizophrenia (45.5%) followed by schizoaffective disorder (15.2%) or bipolar disorder (12.1%). Fourteen patients (42.4%) had a documented history of receiving PP prior to this study and, thus, were reinitiated on PP during their index hospitalization. Of the patients included, a high proportion (78.8%) discontinued their LAIA during the 6 months following discharge.

**TABLE 2: Pearson correlations for primary and secondary outcomes**

	Overlap (n = 13)	No Overlap (n = 20)	r Value	P Value
Primary outcome				
Benztropine use, n (%)				
At PP discontinuation	3 (30) <sup>a</sup>	0 (0) <sup>b</sup>	.457	.019 <sup>c</sup>
At 6 mo	4 (30.77)	3 (15)	.188	.294
Secondary outcomes				
Beta blocker use, n (%)				
At PP discontinuation	1 (10) <sup>a</sup>	1 (6.3) <sup>b</sup>	.068	.740
At 6 mo	1 (7.69)	1 (5)	.055	.761
Diphenhydramine use, n (%)				
At PP discontinuation	0 (0) <sup>a</sup>	0 (0) <sup>b</sup>	... <sup>d</sup>	... <sup>d</sup>
At 6 mo	0 (0)	0 (0)	... <sup>d</sup>	... <sup>d</sup>
Time to PP discontinuation, mean ± SD	106.5 ± 56.65	82.5 ± 52.2	.219	.220
PP discontinued, n (%)	10 (76.92)	16 (80)	-.037	.839
Length of stay, mean ± SD	14.9 ± 16.23	19.4 ± 14	-.151	.402
Psychiatric emergency visits, mean ± SD				
At PP discontinuation	0.7 ± 0.8 <sup>a</sup>	0.1 ± 0.3 <sup>b</sup>	.454	.020 <sup>c</sup>
At 6 mo	1.2 ± 1.1	0.65 ± 1.1	.218	.224
Psychiatric hospitalizations, mean ± SD				
At PP discontinuation	0.6 ± 0.7 <sup>a</sup>	0.1 ± 0.3 <sup>b</sup>	.429	.029 <sup>c</sup>
At 7 mo	0.8 ± 0.8	0.4 ± 0.6	.292	.099

PP = paliperidone palmitate.

<sup>a</sup>This outcome only includes patients who discontinued paliperidone palmitate (n = 10).

<sup>b</sup>This outcome only includes patients who discontinued paliperidone palmitate (n = 16).

<sup>c</sup>Results statistically significant with a 2-tailed alpha of .05.

<sup>d</sup>Correlation is unable to be calculated given constant (0) diphenhydramine prescription claims in both groups.

In the OAP overlap group, most patients received paliperidone (69.2%). Daily doses ranged from 3 to 9 mg with an average of 6 mg. The remainder of the patients received OAP overlap with risperidone with an average daily dose of 4 mg and doses ranging from 1 to 6 mg. The median duration of overlap was 7 days (interquartile range 5 to 42); however, most patients only received OAP overlap while admitted. Four patients (30.7%) were discharged with prescriptions for OAP overlap of 42 to 126 days.

Results for both primary and secondary outcomes are displayed in Table 2. For the primary outcome, benztropine prescription claims, 30% of patients had a documented claim at the time of LAIA discontinuation in the OAP overlap group versus no patients in the no-overlap group. This showed a significant correlation at the time of LAIA discontinuation ( $r = .457$ ,  $P = .019$ ), which was confirmed with a Fisher exact test ( $P = .046$ ). This correlation did not persist at the 6-month time point, at which most patients had discontinued PP (78.8%). There were no prescription claims for diphenhydramine, trihexyphenidyl, or other medications used commonly for EPS at either time point.

For secondary outcomes, a significant correlation was found for both psychiatric emergency visits ( $r = .454$ ,  $P = .02$ ) and hospitalizations ( $r = .429$ ,  $P = .029$ ) at the time of LAIA discontinuation, which were confirmed with *t*-tests ( $P = .02$  and  $P = .029$ , respectively). Once again, these correlations did not persist at the 6-month time point. Despite the smaller number of patients in the OAP group, 53.6% of all psychiatric emergency visits (15/28) and 58.8% of all psychiatric hospitalizations (10/17) occurred in the OAP group. Patients who received OAP overlap were also more likely to have prescription claims for an OAP other than paliperidone or risperidone at the time of LAIA discontinuation (50%,  $n = 10$  vs 19%,  $n = 16$ ). There were no significant correlations found in other secondary outcomes as described in Table 2.

## Discussion

In this study, concurrent oral paliperidone or risperidone use with PP was associated with more frequent prescription claims for benztropine, psychiatric emergency visits, and psychiatric hospitalizations. Because benztropine is commonly used to treat EPS, this finding could indicate that patients who received OAP overlap were more likely

to experience EPS. EPS can be uncomfortable and functionally impairing to patients and represent a leading cause of treatment nonadherence.<sup>22-26</sup> The addition of anticholinergic medications, such as benztropine, can magnify anticholinergic burden, which worsens anticholinergic adverse effects and has been associated with impairments in cognitive and physical function and increased risk of hospitalization and mortality in the elderly.<sup>27-37</sup>

A higher frequency of psychiatric hospitalizations and emergency visits and no difference in length of stay of the index hospitalization was seen with OAP overlap. Although the cause of this increase in hospitalizations and emergency visits cannot be determined, it is likely multifactorial. One possible explanation is that patients who received OAPs had a more severe presentation at baseline, which may have been part of the initial rationale for utilizing OAP overlap. However, in contrast to findings by Hsia et al,<sup>21</sup> we found an increase rather than a reduction in hospitalization with the use of OAP overlap. Our study used a different definition of oral overlap than the  $\geq 7$  days of oral risperidone used by Hsia et al.<sup>21</sup> Patients in our study received higher mean PP maintenance doses (OAP 162 mg vs no-OAP 140.4 mg) compared to patients in the study by Hsia et al<sup>21</sup> (OAP 147 mg vs no-OAP 93 mg). In addition to the differences in maintenance regimens, other confounding variables likely contributed to the differences in our results.

To our knowledge, our study is the first to specifically examine both aspects of safety and outcomes related to psychiatric emergency visits and hospitalizations associated with OAP overlap use with PP. In addition, the study was not limited to the index hospitalization, but followed patients for 6 months after hospital discharge. During this 6-month time point, most patients in both the overlap (76.9%) and no-overlap groups (80%) discontinued their LAIA. Because most patients had discontinued their LAIA, it is unlikely that there would have been additional efficacy or safety changes that resulted after the 6 months.

These results are not without limitations. First, a small sample size from a single institution may have impacted the ability to detect statistically significant differences. Additionally, no baseline assessments of illness severity were collected as these are not routinely collected or systematically documented at the study institution. Thus, baseline illness severity is an important confounding variable that may have influenced our results. Although we did collect some information on concurrent medications, this information was limited, and due to our small sample size, analysis based on concurrent medication use would not have yielded meaningful results. Finally, the study utilizes Medicaid claims data for many of its

outcomes. Although this allowed for patients to be followed for 6 months after discharge regardless of the location of outpatient follow-up, claims data is not without its limitations. Adherence to prescribed oral medications was unable to be assessed. Additionally, inpatient administration of PP given outside of our facility would not have been captured in data collection; some oral medications, such as over-the-counter diphenhydramine, a medication commonly used for EPS, may not be captured by prescription claims data; and information on prescribed frequency, including as needed frequencies, was limited. In addition, this claims data was used as a surrogate marker for adverse effects; however, some providers may have elected to prescribe anticholinergic medications prophylactically or for other indications.

In this study, concurrent oral paliperidone or risperidone use with PP was associated with more frequent prescription claims for benztropine, psychiatric emergency visits, and hospitalizations. Although this could suggest a higher frequency of adverse effects and decompensation in patients with concurrent OAP and LAIA, larger prospective studies with better control for confounding variables would be needed to confirm these results. In addition, although the definition of OAP overlap used in this study was justified by the product labeling, duration of OAP overlap likely impacts both efficacy and safety outcomes, and future studies should evaluate a relationship between duration of OAP overlap and these outcomes.

## References

1. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. *J Clin Psychiatry*. 2016;77(suppl 3):1-24. DOI: [10.4088/JCP.15032su1](https://doi.org/10.4088/JCP.15032su1). PubMed PMID: [27732772](https://pubmed.ncbi.nlm.nih.gov/27732772/).
2. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. *Patient Prefer Adherence*. 2013;7:1171-80. DOI: [10.2147/PPA.S53795](https://doi.org/10.2147/PPA.S53795). PubMed PMID: [24265549](https://pubmed.ncbi.nlm.nih.gov/24265549/); PubMed Central PMCID: [PMC3833623](https://pubmed.ncbi.nlm.nih.gov/PMC3833623/).
3. Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol*. 2014;4(5):198-219. DOI: [10.1177/204512531454029](https://doi.org/10.1177/204512531454029). PMID: [25360245](https://pubmed.ncbi.nlm.nih.gov/25360245/); PubMed Central PMCID: [PMC4212490](https://pubmed.ncbi.nlm.nih.gov/PMC4212490/).
4. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. *J Clin Psychiatry*. 2013;74(10):957-65. DOI: [10.4088/JCP.13ro8440](https://doi.org/10.4088/JCP.13ro8440). PubMed PMID: [24229745](https://pubmed.ncbi.nlm.nih.gov/24229745/).
5. Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. *J Manag Care Spec Pharm*. 2015;21(9):754-68. DOI: [10.18553/jmcp.2015.21.9.754](https://doi.org/10.18553/jmcp.2015.21.9.754). PubMed PMID: [26308223](https://pubmed.ncbi.nlm.nih.gov/26308223/).
6. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophre-

- nia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). *Eur Psychiatry*. 2009;24(5):287-96. DOI: [10.1016/j.eurpsy.2008.12.002](https://doi.org/10.1016/j.eurpsy.2008.12.002). PubMed PMID: [19195847](https://pubmed.ncbi.nlm.nih.gov/19195847/).
7. Subotnik KL, Casaus LR, Ventura J, Luo JS, Helleman GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. *JAMA Psychiatry*. 2015;72(8):822-9. DOI: [10.1001/jamapsychiatry.2015.0270](https://doi.org/10.1001/jamapsychiatry.2015.0270). PubMed PMID: [26107752](https://pubmed.ncbi.nlm.nih.gov/26107752/); PubMed Central PMCID: [PMC5065351](https://pubmed.ncbi.nlm.nih.gov/PMC5065351/).
  8. Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. *Schizophr Res*. 2015;169(1-3):393-9. DOI: [10.1016/j.schres.2015.08.015](https://doi.org/10.1016/j.schres.2015.08.015). PubMed PMID: [26431793](https://pubmed.ncbi.nlm.nih.gov/26431793/).
  9. Aggarwal NK, Sernyak MJ, Rosenheck RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. *J Clin Psychopharmacol*. 2012;32(3):323-8. DOI: [10.1097/JCP.0b013e31825244f6](https://doi.org/10.1097/JCP.0b013e31825244f6). PubMed PMID: [22544006](https://pubmed.ncbi.nlm.nih.gov/22544006/).
  10. Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. *J Clin Psychopharmacol*. 2015;35(4):442-6. DOI: [10.1097/JCP.0000000000000353](https://doi.org/10.1097/JCP.0000000000000353). PubMed PMID: [26075492](https://pubmed.ncbi.nlm.nih.gov/26075492/).
  11. Dimitropoulos E, Drogemuller L, Wong K. Evaluation of concurrent oral and long-acting injectable antipsychotic prescribing at the Minneapolis Veterans Affairs Health Care System. *J Clin Psychopharmacol*. 2017;37(5):605-8. DOI: [10.1097/JCP.0000000000000755](https://doi.org/10.1097/JCP.0000000000000755). PubMed PMID: [28816923](https://pubmed.ncbi.nlm.nih.gov/28816923/).
  12. Alastanos JN, Paxos C, Emshoff J. Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting. *Ment Health Clin [Internet]*. 2019;9(1):18-23. DOI: [10.9740/mhc.2019.01.018](https://doi.org/10.9740/mhc.2019.01.018). PubMed PMID: [30627499](https://pubmed.ncbi.nlm.nih.gov/30627499/); PubMed Central PMCID: [PMC6322819](https://pubmed.ncbi.nlm.nih.gov/PMC6322819/).
  13. Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. Explicit review of risperidone long-acting injection prescribing practice. *J Clin Pharm Ther*. 2010;36(6):651-63. DOI: [10.1111/j.1365-2710.2010.01219.x](https://doi.org/10.1111/j.1365-2710.2010.01219.x). PubMed PMID: [22023342](https://pubmed.ncbi.nlm.nih.gov/22023342/).
  14. Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. *J Clin Psychiatry*. 2011;72(8):1079-85. DOI: [10.4088/JCP.09mo5348yel](https://doi.org/10.4088/JCP.09mo5348yel). PubMed PMID: [21034690](https://pubmed.ncbi.nlm.nih.gov/21034690/).
  15. Janssen Pharmaceuticals, Inc. Invega Sustenna (paliperidone palmitate injection) [prescribing information]. 2006 [updated 2019 Jan; cited 2020 Feb]. Titusville (NJ): DailyMed [Internet]. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554>
  16. Janssen Pharmaceuticals, Inc. Invega Trinza (paliperidone palmitate injection) [prescribing information]. 2006 [updated 2019 Jan; cited 2020 Feb]. Titusville (NJ): DailyMed [internet]. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39e65d7-fa44-4e4c-8b12-a654d3ed0eae>
  17. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. *Clin Pharmacokinet*. 2009;48(9):585-600. DOI: [10.2165/11316870-000000000-00000](https://doi.org/10.2165/11316870-000000000-00000). PubMed PMID: [19725593](https://pubmed.ncbi.nlm.nih.gov/19725593/).
  18. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. *CNS Drugs*. 2011;25(10):829-45. DOI: [10.2165/11591690-000000000-00000](https://doi.org/10.2165/11591690-000000000-00000). PubMed PMID: [21936586](https://pubmed.ncbi.nlm.nih.gov/21936586/).
  19. Russu A, Kern Sliwa J, Ravenstijn P, Singh A, Mathews M, Kim E, et al. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: practical guidance based on pharmacokinetic simulations. *Int J Clin Pract*. 2018;72(6):e13089. DOI: [10.1111/ijcp.13089](https://doi.org/10.1111/ijcp.13089). PubMed PMID: [29707876](https://pubmed.ncbi.nlm.nih.gov/29707876/); PubMed Central PMCID: [PMC6175146](https://pubmed.ncbi.nlm.nih.gov/PMC6175146/).
  20. Ascher-Svanum H, Peng X, Montgomery W, Faries DE, Lawson AH, Witte MM, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. *Eur Psychiatry*. 2011;26(5):313-9. DOI: [10.1016/j.eurpsy.2010.03.015](https://doi.org/10.1016/j.eurpsy.2010.03.015). PubMed PMID: [20621454](https://pubmed.ncbi.nlm.nih.gov/20621454/).
  21. Hsia SL, Leckband SG, Rao S, Jackson E, Lacro JP. Dosing strategies for switching from oral risperidone to paliperidone palmitate: effects on clinical outcomes. *Ment Health Clin [Internet]*. 2017;7(3):95-100. DOI: [10.9740/mhc.2017.05.095](https://doi.org/10.9740/mhc.2017.05.095). PubMed PMID: [29955505](https://pubmed.ncbi.nlm.nih.gov/29955505/); PubMed Central PMCID: [PMC6007563](https://pubmed.ncbi.nlm.nih.gov/PMC6007563/).
  22. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. *Acta Psychiatr Scand Suppl*. 2002;407:83-6. DOI: [10.1034/j.1600-0447.2000.00016.x](https://doi.org/10.1034/j.1600-0447.2000.00016.x). PubMed PMID: [11261648](https://pubmed.ncbi.nlm.nih.gov/11261648/).
  23. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. *Drug Saf*. 2005;28(3):191-208. DOI: [10.2165/00002018-200528030-00002](https://doi.org/10.2165/00002018-200528030-00002). PubMed PMID: [15733025](https://pubmed.ncbi.nlm.nih.gov/15733025/).
  24. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. *Ann Clin Psychiatry*. 2002;14(1):47-57. DOI: [10.1023/a:1015276028425](https://doi.org/10.1023/a:1015276028425). PubMed PMID: [12046640](https://pubmed.ncbi.nlm.nih.gov/12046640/).
  25. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. *Ann Clin Psychiatry*. 2002;14(2):123-9. DOI: [10.1023/a:1016811222688](https://doi.org/10.1023/a:1016811222688). PubMed PMID: [12238737](https://pubmed.ncbi.nlm.nih.gov/12238737/).
  26. Hummer M, Fleischhacker WW. Compliance and outcome in patients treated with antipsychotics. *CNS Drugs*. 1996;5(Suppl 1):13-20. DOI: [10.2165/00023210-199600051-00004](https://doi.org/10.2165/00023210-199600051-00004).
  27. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. *Arch Intern Med*. 2007;167(8):781-7. DOI: [10.1001/archinte.167.8.781](https://doi.org/10.1001/archinte.167.8.781). PubMed PMID: [17452540](https://pubmed.ncbi.nlm.nih.gov/17452540/).
  28. Tsoutsoulas C, Mulsant BH, Kumar S, Ghazala Z, Voineskos AN, Menon M, et al. Anticholinergic burden and cognition in older patients with schizophrenia. *J Clin Psychiatry*. 2017;78(9):e1284-90. DOI: [10.4088/JCP.17m11523](https://doi.org/10.4088/JCP.17m11523). PubMed PMID: [29188908](https://pubmed.ncbi.nlm.nih.gov/29188908/).
  29. De Vreese LP, Mantesso U, De Bastiani E, Marangoni A, Weger E, Gomiero T. Anticholinergic burden in adult and elderly people with intellectual disabilities: results from an Italian multicenter cross-sectional study. *PLoS One*. 2018;13(10):e0205897. DOI: [10.1371/journal.pone.0205897](https://doi.org/10.1371/journal.pone.0205897). PubMed PMID: [30379948](https://pubmed.ncbi.nlm.nih.gov/30379948/); PubMed Central PMCID: [PMC6209221](https://pubmed.ncbi.nlm.nih.gov/PMC6209221/).
  30. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. *BMC Geriatr*. 2015;15:31. DOI: [10.1186/s12877-015-0029-9](https://doi.org/10.1186/s12877-015-0029-9). PubMed PMID: [25879993](https://pubmed.ncbi.nlm.nih.gov/25879993/); PubMed Central PMCID: [PMC4377853](https://pubmed.ncbi.nlm.nih.gov/PMC4377853/).
  31. Kumpula E-K, Bell JS, Soini H, Pitkälä KH. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. *J Clin Pharmacol*. 2013;51(2):256-63. DOI: [10.1177/0091270010368410](https://doi.org/10.1177/0091270010368410). PubMed PMID: [20489026](https://pubmed.ncbi.nlm.nih.gov/20489026/).
  32. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and falls in older people in residential aged care. *J Am Geriatr Soc*. 2011;59(5):875-80. DOI: [10.1111/j.1532-5415.2011.03386.x](https://doi.org/10.1111/j.1532-5415.2011.03386.x). PubMed PMID: [21539525](https://pubmed.ncbi.nlm.nih.gov/21539525/).
  33. Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, et al. Cognitive burden of anticholinergic medications in psychotic disorders. *Schizophr Res*. 2017;190:129-35. DOI: [10.1016/j.schres.2017.03.034](https://doi.org/10.1016/j.schres.2017.03.034). PubMed PMID: [28390849](https://pubmed.ncbi.nlm.nih.gov/28390849/).

34. Panula J, Puustinen J, Jaatinen P, Vahlberg T, Aarnio P, Kivela S-L. Effects of potent anticholinergics, sedatives and antipsychotics on postoperative mortality in elderly patients with hip fracture. *Drugs Aging*. 2009;26(11):963-71. DOI: [10.2165/11317660-000000000-00000](https://doi.org/10.2165/11317660-000000000-00000). PubMed PMID: [19848441](https://pubmed.ncbi.nlm.nih.gov/19848441/).
35. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. *Am J Psychiatry*. 2009;166(9):1055-62. DOI: [10.1176/appi.ajp.2009.09010017](https://doi.org/10.1176/appi.ajp.2009.09010017). PubMed PMID: [19570929](https://pubmed.ncbi.nlm.nih.gov/19570929/); PubMed Central PMCID: [PMC3735363](https://pubmed.ncbi.nlm.nih.gov/PMC3735363/).
36. Kim S-J, Jung D, Shim J-C, Moon J-J, Jeon D-W, Kim Y-N, et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. *Asian J Psychiatr*. 2019;46:111-7. DOI: [10.1016/j.ajp.2019.10.013](https://doi.org/10.1016/j.ajp.2019.10.013). PubMed PMID: [31654923](https://pubmed.ncbi.nlm.nih.gov/31654923/).
37. Ang MS, Abdul Rashid NA, Lam M, Rapisarda A, Kraus M, Keefe RSE, et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. *J Clin Psychopharmacol*. 2017;37(6):651-6. DOI: [10.1097/JCP.0000000000000790](https://doi.org/10.1097/JCP.0000000000000790). PubMed PMID: [29016375](https://pubmed.ncbi.nlm.nih.gov/29016375/); PubMed Central PMCID: [PMC5680994](https://pubmed.ncbi.nlm.nih.gov/PMC5680994/).